ArticleOpen forum infectious diseases2019
Long-Acting Lipoglycopeptides: "Lineless Antibiotics" for Serious Infections in Persons Who Use Drugs.
Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 62 citations in OpenAlex.
- Oritavancin for the Treatment ofOpen forum infectious diseases · 2025Trial
- Optimizing Treatment of Infective Endocarditis in Patients Who Inject Drugs.Antibiotics (Basel, Switzerland) · 2026Review
- Reply to the comment on: "Dalbavancin for infective endocarditis: a systematic review of effectiveness, safety, and dosing".European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Comment on: "Dalbavancin for infective endocarditis: a systematic review of effectiveness, safety, and dosing".European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Tricuspid valve endocarditis in people who inject drugs: strategies to reduce mortality and recurrent infection.Annals of cardiothoracic surgery · 2026Review
- Implementation and outcomes of a multifaceted care model for people experiencing homelessness and people who inject drugs hospitalized with complicated infections.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Budget Impact and Financial Analysis of Outpatient Dalbavancin in an Urban, Non-Teaching, Community Hospital.Clinical drug investigation · 2025Article
- Bacterial and fungal infections in persons who inject drugs.Clinical microbiology reviews · 2025Review
- Is intravenous aciclovir overused in possible viral encephalitis? a retrospective review.Journal of neurology · 2025Article
- Impact of Substance Use Disorders on Outcomes of Medically Insured Persons Receiving Multiweek Outpatient Parenteral Antimicrobial Therapy: a Claims-based Cohort Study From 2015 to 2020.Open forum infectious diseases · 2025Article
- Delivery of Outpatient Parenteral Antimicrobial Therapy (OPAT) in an Ever-Changing National Health Service (UK): Benefits, Barriers, and Opportunities.Antibiotics (Basel, Switzerland) · 2025Review
- Common Bacterial Infections in Persons Who Inject Drugs.Medicines (Basel, Switzerland) · 2025Review
- A Bundle of the "Top 10" Outpatient Parenteral Antimicrobial Therapy Publications in 2023.Open forum infectious diseases · 2024Review
- Management of People Who Inject Drugs With Serious Injection-Related Infections in an Outpatient Setting: A Scoping Review.Open forum infectious diseases · 2024Article
- Three-years of dalbavancin use at a UK tertiary referral hospital serving a population with high numbers of people who inject drugs.JAC-antimicrobial resistance · 2024Article
- Navigating Antibacterial Frontiers: A Panoramic Exploration of Antibacterial Landscapes, Resistance Mechanisms, and Emerging Therapeutic Strategies.ACS infectious diseases · 2024Review
- Strategies to Improve Patient-Centered Care for Drug Use-Associated Infective Endocarditis: JACC Focus Seminar 2/4.Journal of the American College of Cardiology · 2024Review
- Real-World Dalbavancin Use for Serious Gram-Positive Infections: Comparing Outcomes Between People Who Use and Do Not Use Drugs.Open forum infectious diseases · 2024Article
- Dalbavancin Use in Persons Who Use Drugs May Increase Adherence Without Increasing Cost.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInjection drug use is associated with serious infections. Due to challenges with medical management of addiction, relapses and additional infections are common. Persons who use drugs (PWUD) are more likely to leave against medical advice before completing treatment, which could result in treatment failure. Prolonged intravenous (IV) antimicrobial therapy in PWUD may be complicated by concern for IV catheter misuse, sometimes requiring prolonged hospitalization. Ideal alternatives would provide the following: (1) high success rate; (2) reduced rate of medical complications; (3) improved safety profiles; and (4) improved cost-effectiveness. Long-acting lipoglycopeptides present such opportunity for treatment of serious Gram-positive infections.
methodsWe performed a system-wide, retrospective analysis of adults admitted to University of Colorado Health from September 2015 to June 2018 and treated with dalbavancin or oritavancin based on clinical judgment of their treating physicians.
resultsFifty-six patients met inclusion criteria (17 PWUD vs 39 non-PWUD). The PWUD group were younger, healthier by Charlson comorbidity index, more likely insured by Medicaid, and admitted for conditions requiring longer treatment. Ten patients were lost to follow-up. Of the patients with follow-up, clinical failure was met in 1 PWUD patient (6%) and 6 non-PWUD patients (15%) (
conclusionsLong-acting lipoglycopeptides may be equally effective as standard-of-care, present a safety advantage, and secure earlier discharge and significant cost-savings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.